Highlights CanSino Biologics Inc.

Equities

6185

CNE100003F01

Delayed Hong Kong S.E. Other stock markets 10:54:40 27/06/2024 am IST			5-day change	1st Jan Change
19.5 ^HKD	-3.47%		-2.60%	-17.28%

24/06	Cansino Biologics' Senior Management to Boost Stakeholding	MT
10/06	Indonesia ramps up fight against tuberculosis amid concerns on economic impact	RE

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Cansino Biologics' Senior Management to Boost Stakeholding	24/06	MT
Cansino Biologics Invests 160 Million Yuan in China Bohai Bank’s Structured Deposits	21/05	MT
CanSino Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04	CI
Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine	22/04	MT
CanSino Biologics Inc. Obtains Clinical Trial Approval Granted by the National Medical Products Administration of the People's Republic of China	22/04	CI
Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results	22/04	MT
Cansino Biologics Begins Phase III Clinical Trials for Tetanus Drug	21/03	MT
Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine	20/03	CI
CanSino Biologics Sued by Brazilian Pharma Firm Belcher Over COVID-19 Vaccine Dispute	14/03	MT
Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine	28/02	CI
CanSino Biologics' Loss Widens in 2023, Misses EPS, Revenue Estimates; Shares Rise 4%	26/02	MT
CanSino Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02	CI
CanSino Biologics' Loss to Widen in 2023; Shares Drop 5%	31/01	MT
Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023	30/01	CI
CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine	30/01	CI
Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine	15/01	CI
CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine	20/12	CI
Cansino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Enrollment for TDCP Adolescent and Adult	06/12	CI
CanSino Biologics' COVID-19 Vaccine Included for China's Emergency Use	04/12	MT
CanSino Biologics Inc. announces Recombinant Covid-19 Xbb.1.5 Variant Vaccine Forinhalation (Adenovirus Type 5 Vector) Included for Emergency Use	03/12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

INTERVIEW - Xuefeng Yu, CEO of CanSino Biologics: Behind the scenes of the agreement with AstraZeneca

August 31, 2023 at 03:38 pm IST